The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
175 jobs Number of planned job losses
Announcement Date
15 June 2021
Employment effect (start)
15 June 2021
Foreseen end date
Description
As announced on 15 June 2021, the UK-based pharmaceutical company AstraZeneca will be closing its site in Wedel which will result in the dismissal of 175 employees in the production. The decision has been made as a reaction to the market demand for the products. A social plan will be implemented by the end of 2021.
In addition to the production site's closure, the headquarters will be relocated from Wedel to Hamburg. The new headquarters will allow AstraZeneca to continue to grow and implement new modern forms of working.
AstraZeneca has approximately 900 employees in Germany.
Eurofound (2021), AstraZeneca, Closure in Germany, factsheet number 104969, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/104969.